Navigation Links
Study examines how breastfeeding impacts cost of care for very low birth weight infants
Date:12/16/2008

(CHICAGO) The National Institutes of Health (NIH) has awarded nearly $3 million to support Rush University Medical Center's study analyzing how human breast milk impacts the health outcomes and health care cost savings for very low birth weight infants babies less than 1500 grams.

The grant will enable researchers at Rush to conduct a five-year study involving the largest prospective cohort of 600 very low birth weight infants born to racially and economically diverse mothers. The study will have a representative number of African American and low income women enrolled in this study.

"Unlike other institutions with the same demographics, the mothers that give birth at Rush elect to provide breast milk because they are encouraged to think of their milk as 'medicine' for their babies," said Paula Meier, director of clinical research and lactation in the Rush neonatal intensive care unit (NICU) and principal investigator of the study.

More than 95 percent of very low birth weight infants in Rush's NICU receive their mothers' breast milk and will be enrolled into the study.

The trial will examine the relationship between the amount, the duration, and the timing of human milk feedings and improved health outcomes for very low birth weight babies hospitalized in the NICU.

Past research indicates that human milk protects very low birth weight infants from prematurity-specific complications that predispose these infants to short-and long-term health problems and increase cost of health care.

"However, no one has conclusively linked the amount and length of time these infants need to be fed human milk in order to lower their health risks and tie it back to cost of care," said Meier.

"For this patient population, human milk is much more important for its therapeutic and medicinal properties rather than nutrition," said Meier. "While these infants are in the NICU, we have a critical window to decrease m
'/>"/>

Contact: Deborah Song
deb_song@rush.edu
312-942-0588
Rush University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Abused women seek more infant health care, MU study finds
2. New Easter Seals-MassMutual Study: Autism Strains Family Finances, Threatens Long-Term Care and Security
3. Easter Seals Study Sheds New Light on Parents Life-Long Fears, Anxieties and Critical Supports Needed to Raise a Child With Autism
4. QLT announces interim results of radical study evaluating Visudyne combination therapy
5. Newly discovered esophagus stem cells grow into transplantable tissue, Penn study finds
6. Study to identify best rehabilitation therapies for patients with traumatic brain injuries
7. Double Blind Study Proves The Pink Patch Works for Weight Loss
8. First Patient from CyberKnife Center of Palm Beach Enrolled in Worldwide Landmark Study of Operable Lung Cancer Patients
9. Planned safety analysis of a breast cancer prevention study reveals encouraging news for Exemestane
10. Genomic Health Announces Study Establishing the Utility of Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated with Aromatase Inhibitors
11. Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...tailing plastic surgery procedures is now availabl...dates can view procedures and print out informatio... (PRWEB) December 2, 2009 -- Recovery..., has always been dedicated to providing resources...es, providing liposuction garments, breast augment...
(Date:12/2/2009)...uthor James A. Feinstein, MD, has just released hi...s from Patients on Becoming a Doctor, that traces ...hool--the grueling clinical year. , ...009 -- Most people will, at some point or another,... gown or staring at someone else dressed in a tiny...
(Date:12/2/2009)...e-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: G...y Health Care Conference today at 2:30 p.m. Easter...t live and may be accessed through a link on the i...n-probe.com . The webcast will be available for 30... ,, Gen-Probe Incorporated is a global leader ...
(Date:12/2/2009)...wire/ -- LeapFrog Investments has announced a ZAR ...fe, the innovative South African insurer serving p... brings together LeapFrog, the leading microinsura...most innovative insurance businesses. The announce...fe has developed a distinctive and profitable busi...
(Date:12/2/2009)...cal trial presented today at the annual meeting of...provide the first strong evidence of the benefit o... breasts who are at elevated risk for breast cance...ghly sensitive in depicting early breast cancer. ,... in addition to mammography significantly improves...
Breaking Medicine News(10 mins):Health News:Online Compression Garments Retailer Introduces 3D Animation of Surgical Procedures 2Health News:Beneath the Short White Coat: A Medical Student Reveals All 2Health News:Gen-Probe to Webcast Presentation at the 21st Annual Piper Jaffray Health Care Conference Today 2Health News:LeapFrog Invests $6M in AllLife, Innovative African HIV and Diabetes Insurer 2Health News:LeapFrog Invests $6M in AllLife, Innovative African HIV and Diabetes Insurer 3Health News:Annual screening with breast ultrasound or MRI could benefit some women 2
...spital which is to be built on the site of Birming...gnal. The plans for this new ?600m super hospital .../. It is funded by a private finance initiative. ...ble. The Treasury has also approved the schem...
...ying a drive for better hygiene at rural levels, t... its threats against panchayat leaders who fail to...s. Last year the state assembly had amended th...lush in their homes within a year of being elected...
...ts have discovered that watching television for an...167 calories thereby adding over than six kilogram...ve discovered that watching television for an hour...n the first to put an exact figure has been put on...
...ead of the NHS, Sir Ian Carruthers, has proposed c...million NHS deficit//. He proposes to unveil h...ony Blair. Sir Ian believes the ?10.3 billion spen... they could benefit have arisen. NHS had been ...
...s syndrome, a common running ailment, can be treat...g to Dr. Ronald Adler, chief, Division of Ultrasou...be used to accurately diagnose the ailment and rel...ed by the back of the shoe consistently rubbing ag...
...who was convicted of murdering Lin Russell and her...he publication of a report that probes the failure...ling spree. // The independent report by Robert..., Josie and her father, Shaun wants the report to ...
Other Medicine News:Health News:Madhya Pradesh To Concentrate On Better Rural Hygiene 2Health News:Watching TV Blamed for Weight Gain 2Health News:Proper Diagnosis Could Augment Speedy Recovery Of Haglund’s Syndrom 2
(Date:12/1/2009)...., Dec. 1 CeloNova BioSciences, In... medical devices and of specialty implants, today ..., founder and medical director of Baptist Cardiac ...iscuss the CATANIA(TM) Stent System with NanoThin ...lar Interventions Conference to be held at the Hot...
(Date:12/1/2009)... and TOKYO, Dec. 1 Galenea Corp. a... the further extension of their research and devel...tension increases the collaboration term to seven ...proximately $90 million. The companies have been ...of discovering and developing first-in-class thera...
(Date:12/1/2009)...., Dec. 1 SCOLR Pharma, ... 20, 2009 it licensed to Chrono Nutraceuticals LLC...l four extended release dietary supplements using ...rm. In addition, SCOLR granted Chrono rights to m...ited States on a nonexclusive basis. Chrono paid ...
Breaking Medicine Technology:Dr. Barry Katzen to Present CATANIA(TM) Coronary Stent Data in Tel Aviv 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 3SCOLR Pharma, Inc. Licenses Dietary Supplements 2SCOLR Pharma, Inc. Licenses Dietary Supplements 3American Nurses Association Joins the National Healthcare Career Network 54285 1American Nurses Association Joins the National Healthcare Career Network 54285 2American Nurses Association Joins the National Healthcare Career Network 54285 3Scientist Verifies That The Ancient Practice Of Girding The Loins Increases Health 54281 1Scientist Verifies That The Ancient Practice Of Girding The Loins Increases Health 54281 2Scientist Verifies That The Ancient Practice Of Girding The Loins Increases Health 54281 3The tourist trap 9540 1
...ial New Front-Line Treatment ...Genzyme Corp.,(Nasdaq: GENZ ) reported preliminar...2 study examining the safety and effectiveness of ...ously untreated, older adult,patients with acute m...fit,from conventional "7+3" anthracycline plus cyt...
...CALS, INC. (Nasdaq: VION ) today announced that i... lead anticancer agent Cloretazine(R),(VNP40101M) ...yelogenous,leukemia (AML) had been presented at th...linical Oncology (ASCO(R)) in Chicago, Illinois., ...atients. The median,age of these patients was 73 y...
Other Medicine Technology:Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 3Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 4Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 5Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 6Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 7Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 8Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 2Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 3Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 4
Fast-Cath™ Guiding Introducers
Lumenis 1000 Integrated Slit Lamp
Novus 30001
Selecta Trio Photocoagulator and SLT Combination Laser
Medicine Products: